Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

By Lon S. Schneider, Karen Stevens Dagerman, P. Insel. Journal of the American Medical Association (JAMA), 2005

1,676 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study (2007, background): “Evidence from randomized controlled trials suggest that use of one category of neuroleptics—atypical neuroleptics—result in increased death rates compared to placebo [11].”
Antipsychotic Drug Use and Mortality in Older Adults with Dementia (2007, background): “The meta-analysis by Schneider and colleagues (14) includes 15 RCTs that evaluated several atypical antipsychotics in the short-term management of neuropsychiatric symptoms of dementia.”
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline (2007, background): “There are recent reports that atypical antipsychotic medication may be associated with an increased risk of cerebrovascular events and mortality in elderly patients with dementia [234–237].”
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. (2006, neutral): “Moreover, the available data on efficacy have been inconsistent, and new safety issues have emerged with respect to increased risks of cerebrovascular disease(2,3) as well as death.(1,4) To address some of these concerns, the current investigators conducted a double-blind, placebocontrolled trial to”